Filing Details

Accession Number:
0000899243-17-018014
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-07-06 18:26:35
Reporting Period:
2017-07-05
Filing Date:
2017-07-06
Accepted Time:
2017-07-06 18:26:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1420565 Aileron Therapeutics Inc ALRN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1709976 Jr. M. Brian Gallagher C/O S.r. One, Limited
161 Washinton Street, Suite 500
Conshohocken PA 19428
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-07-05 1,158,186 $0.00 1,158,186 No 4 C Indirect See Footnote
Common Stock Acquisiton 2017-07-05 273,333 $15.00 1,431,519 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series D Preferred Stock Disposition 2017-07-05 6,781,770 $0.00 682,476 $0.00
Common Stock Series E-2 Preferred Stock Disposition 2017-07-05 1,471,551 $0.00 148,088 $0.00
Common Stock Series E-3 Preferred Stock Disposition 2017-07-05 1,276,389 $0.00 128,448 $0.00
Common Stock Series F Preferred Stock Disposition 2017-07-05 1,979,188 $0.00 199,173 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series D, Series E-2, Series E-3 and Series F Preferred converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares. Dr. Brian M. Gallagher, Jr. is a partner and Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect wholly-owned subsidiary of GlaxoSmithKline plc. Dr. Gallagher disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.